-
- COVID-19
Jul 06, 2026Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. FDA Approval of Xocova® for COVID-19 Prevention -
- Highly pathogenic avian influenza virus (HPAIV)
Jun 04, 2026Evaluation of the Efficacy of Low-Concentration Gaseous Chlorine Dioxide in Inactivating Airborne H5 High Pathogenicity Avian Influenza Virus in Vivo Model -
- COVID-19
Jun 01, 2026Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. FDA Approval of Xocova® for COVID-19 Prevention -
- probiotics
Oct 31, 2025Enhancement of Vaccine-Induced T-Cell Responses by Probiotics in Calves -
- IgA
- Zirconia Particles
Aug 29, 2025Purification of Immunoglobulin A Using Mesoporous Zirconia Particles Coated with Phosphate -
- SARS-CoV-2
Jul 29, 2025SARS-CoV-2 uptake and inflammatory response in senescent endothelial cells are regulated by the BSG/VEGFR2 pathway -
- CTLA-4
- PD-L1
May 20, 2025Development of caninized anti-CTLA-4 antibody as salvage combination therapy for anti-PD-L1 refractory tumors in dogs -
- SARS-CoV-2
- COVID-19
Apr 21, 2025Malabaricone C isolated from edible plants as a potential inhibitor of SARS-CoV-2 infection -
- 脂質ナノ粒子
Apr 17, 2025Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery -
- Expression Vector
Apr 07, 2025The host-vector system developed jointly with Fuso Pharmaceutical Industries, Ltd. has been commercialized by the company. -
- COVID-19
Apr 01, 2025Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. has submitted a rolling submission to the U.S. Food and Drug Administration (FDA) for Xocova as a prevention measure against COVID-19. -
- COVID-19
Mar 27, 2025Collaboration with Shionogi for drug discovery –Shionogi & Co., Ltd. submitted an application in Japan for an additional indication of new coronavirus treatment Xocova for the prevention of COVID-19.
